November 5, 2026

Dear All,

Company Name: Delta-Fly Pharma, Inc.
(Code number : 4598 TSE Growth Market)
Inquiries: Kenzo Iizuka, Senior Vice President, R&D
(Contact: https://www.delta-flypharma.co.jp/en/contactentrance/)

Announcement Regarding the Acceptance of Two DFP-10917 Clinical Study Presentations at ASH 2026

Delta-Fly Pharma, Inc. is pleased to announce that two presentations covering the clinical development of DFP-10917 have been accepted for presentation at the 2026 Annual Meeting of the American Society of Hematology (ASH): one on the Phase 3 clinical study of DFP-10917 as a monotherapy and the other on the Phase 1/2 clinical study of DFP-10917 in combination with venetoclax.

1. Phase 3 Clinical Study of DFP-10917

Title : A Phase 3 Randomized Trial of DFP-10917 Versus Investigator-Selected Non-Intensive or Intensive Reinduction Therapy in Patients with Acute Myeloid Leukemia Receiving Second-, Third-, or Fourth-Line Salvage Treatment
Session : Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Presentation Date: December 12, 2026
Presentation Time: 5:30 PM–7:30 PM
URL: https://onlineprogram.hematology.org/paper-details.aspx?pid=682760

2. Phase 1/2 Clinical Study of DFP-10917 in Combination with Venetoclax

Title : Phase 1/2 Study of DFP-10917 in Combination with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Session : 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Presentation Date: December 14, 2026
Presentation Time: 6:00 PM–8:00 PM
URL: https://onlineprogram.hematology.org/paper-details.aspx?pid=682770

About ASH 2026

The 2026 Annual Meeting of the American Society of Hematology (ASH) will be held in New Orleans, Louisiana, from December 12 to 15, 2026. It is one of the world's leading international scientific meetings in the field of hematology.

The acceptance of these two presentations at ASH 2026 represents an important opportunity to share clinical development data on DFP-10917, both as a monotherapy and in combination with venetoclax, with hematology experts worldwide.

Delta-Fly Pharma will continue to advance the clinical development of DFP-10917, with the aim of providing new treatment options for patients with relapsed or refractory acute myeloid leukemia (R/R AML).

END